Small Molecules

21 Oct 2017 Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis
20 Oct 2017 DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint
20 Oct 2017 Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994
20 Oct 2017 Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
19 Oct 2017 Biscayne Neurotherapeutics Reports Successful Phase 1b Clinical Trial Results For Its Novel Antiepileptic Agent
19 Oct 2017 Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase 2a
19 Oct 2017 Esanex Announces First Patient Dosed in an Open-Label Study of SNX-5422 in Chronic Lymphocytic Leukemia
19 Oct 2017 Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda
19 Oct 2017 Tyme’s SM-88 Demonstrates Prolonged Overall Survival in Metastatic Cancer Patients Across Multiple Subgroups
19 Oct 2017 Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
18 Oct 2017 Synspira Announces First Patient Dosed in Phase 1a Study of SNSP113 in Cystic Fibrosis
18 Oct 2017 U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review
17 Oct 2017 Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Esophageal Cancer
17 Oct 2017 MEBIAS Discovery LLC Presents Pre-Clinical Data on Mu Opioid Receptor Pain Compounds at ADDC
17 Oct 2017 Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases
17 Oct 2017 AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
17 Oct 2017 Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial
17 Oct 2017 Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer
17 Oct 2017 Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
16 Oct 2017 Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer
14 Oct 2017 Faslodex (fulvestrant) receives positive CHMP opinion for the treatment of hormone receptor-positive advanced breast cancer in combination with palbociclib1
14 Oct 2017 CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC
13 Oct 2017 CHMP Issues a Positive Opinion on Janssen’s ZYTIGA® to Include Earlier Stage Prostate Cancer Patients
12 Oct 2017 Spinal Muscular Atrophy Program Advances into Pivotal Study in SMA Patients
12 Oct 2017 Vidac Pharma Reports Positive Results from Phase 2a Proof-of-Concept Trial of VDA-1102 Ointment in Actinic Keratosis

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing